Published in J Infect Dis on July 01, 2011
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
A cornucopia of human polyomaviruses. Nat Rev Microbiol (2013) 2.08
Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry (2013) 1.63
Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis (2011) 1.32
JC virus granule cell neuronopathy is associated with VP1 C terminus mutants. J Gen Virol (2011) 1.25
Frequent infection of cortical neurons by JC virus in patients with progressive multifocal leukoencephalopathy. J Neuropathol Exp Neurol (2012) 1.24
Progressive multifocal leukoencephalopathy: clinical and molecular aspects. Rev Med Virol (2011) 1.13
Natalizumab-treated patients at high risk for PML persistently excrete JC polyomavirus. J Neurovirol (2016) 1.06
A retrograde trafficking inhibitor of ricin and Shiga-like toxins inhibits infection of cells by human and monkey polyomaviruses. MBio (2013) 1.00
Polyomavirus JC in the context of immunosuppression: a series of adaptive, DNA replication-driven recombination events in the development of progressive multifocal leukoencephalopathy. Clin Dev Immunol (2013) 0.96
Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding. MBio (2013) 0.95
Immune surveillance and response to JC virus infection and PML. J Neurovirol (2013) 0.91
JC polyomavirus attachment, entry, and trafficking: unlocking the keys to a fatal infection. J Neurovirol (2014) 0.89
Detection of JC virus-specific immune responses in a novel humanized mouse model. PLoS One (2013) 0.89
Human glial chimeric mice reveal astrocytic dependence of JC virus infection. J Clin Invest (2014) 0.88
Inter- and intralaboratory comparison of JC polyomavirus antibody testing using two different virus-like particle-based assays. Clin Vaccine Immunol (2014) 0.87
T cell epitope mapping of JC polyoma virus-encoded proteome reveals reduced T cell responses in HLA-DRB1*04:01+ donors. J Virol (2013) 0.87
JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog (2014) 0.86
Mutations in the GM1 binding site of simian virus 40 VP1 alter receptor usage and cell tropism. J Virol (2012) 0.85
Efficient uptake of blood-borne BK and JC polyomavirus-like particles in endothelial cells of liver sinusoids and renal vasa recta. PLoS One (2014) 0.83
The Greater Affinity of JC Polyomavirus Capsid for α2,6-Linked Lactoseries Tetrasaccharide c than for Other Sialylated Glycans Is a Major Determinant of Infectivity. J Virol (2015) 0.80
Broadly neutralizing human monoclonal JC polyomavirus VP1-specific antibodies as candidate therapeutics for progressive multifocal leukoencephalopathy. Sci Transl Med (2015) 0.80
Viral miRNAs in plasma and urine divulge JC polyomavirus infection. Virol J (2014) 0.79
Association between the JC polyomavirus infection and male infertility. PLoS One (2012) 0.78
An animal model for progressive multifocal leukoencephalopathy. J Clin Invest (2014) 0.78
JC polyomavirus (JCV) and monoclonal antibodies: friends or potential foes? Clin Dev Immunol (2013) 0.78
Human polyomavirus receptor distribution in brain parenchyma contrasts with receptor distribution in kidney and choroid plexus. Am J Pathol (2015) 0.77
Paediatric use of mycophenolate mofetil. Br J Clin Pharmacol (2013) 0.77
A Difficult Decision: Atypical JC Polyomavirus Encephalopathy in a Kidney Transplant Recipient. Transplantation (2016) 0.76
JC Polyomavirus Abundance and Distribution in Progressive Multifocal Leukoencephalopathy (PML) Brain Tissue Implicates Myelin Sheath in Intracerebral Dissemination of Infection. PLoS One (2016) 0.76
Trichodysplasia spinulosa-Associated Polyomavirus Uses a Displaced Binding Site on VP1 to Engage Sialylated Glycolipids. PLoS Pathog (2015) 0.76
Increased frequency of JC-polyomavirus detection in rheumatoid arthritis patients treated with multiple biologics. Med Microbiol Immunol (2015) 0.76
Progressive multifocal leukoencephalopathy development is associated with mutations in JC virus capsid protein VP1 that change the receptor specificity of the virus. J Infect Dis (2011) 0.76
Type I Interferons Regulate the Magnitude and Functionality of Mouse Polyomavirus-Specific CD8 T Cells in a Virus Strain-Dependent Manner. J Virol (2016) 0.75
The importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathy. Front Immunol (2015) 0.75
In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection. Viruses (2016) 0.75
Depletion of CpG Dinucleotides in Papillomaviruses and Polyomaviruses: A Role for Divergent Evolutionary Pressures. PLoS One (2015) 0.75
Deep-sequence identification and role in virus replication of a JC virus quasispecies in patients with progressive multifocal leukoencephalopathy. J Virol (2016) 0.75
JC Polyomavirus Attachment and Entry: Potential Sites for PML Therapeutics. Curr Clin Microbiol Rep (2017) 0.75
Clustal W and Clustal X version 2.0. Bioinformatics (2007) 126.47
Seroepidemiology of human polyomaviruses. PLoS Pathog (2009) 4.62
Pathogenesis and molecular biology of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (1992) 3.32
Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis (2009) 3.23
Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J Neuroimmune Pharmacol (2006) 3.13
Establishment of a line of human fetal glial cells that supports JC virus multiplication. Proc Natl Acad Sci U S A (1985) 2.93
Diversity in the sialic acids. Glycobiology (1992) 2.60
Progressive multifocal leukoencephalopathy in HIV-1 infection. Lancet Infect Dis (2009) 1.82
Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids. J Virol (1998) 1.80
Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol (1992) 1.61
Structure-function analysis of the human JC polyomavirus establishes the LSTc pentasaccharide as a functional receptor motif. Cell Host Microbe (2010) 1.60
Particle counts of haemagglutinating viruses. J Gen Microbiol (1955) 1.58
Genetic and structural analysis of a virulence determinant in polyomavirus VP1. J Virol (1995) 1.52
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis (2005) 1.47
Reemergence of PML in natalizumab-treated patients--new cases, same concerns. N Engl J Med (2009) 1.46
Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology (1992) 1.44
Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet (2009) 1.43
Cellular and humoral immune response in progressive multifocal leukoencephalopathy. Ann Neurol (2001) 1.35
Sphingolipids and gangliosides of the nervous system in membrane function and dysfunction. FEBS Lett (2009) 1.25
Oligosaccharides as receptors for JC virus. J Virol (2002) 1.25
Progressive multifocal leucoencephalopathy: detection of papovavirus JC in kidney tissue. J Med Virol (1983) 1.24
The Polyomaviridae: Contributions of virus structure to our understanding of virus receptors and infectious entry. Virology (2009) 1.15
Progressive multifocal leukoencephalopathy: investigation of three cases using in situ hybridization with JC virus biotinylated DNA probe. Ann Neurol (1985) 1.15
JC virus infection in allograft kidneys: analysis by polymerase chain reaction and immunohistochemistry. Transplantation (2001) 1.06
Comparison of real-time PCR and hemagglutination assay for quantitation of human polyomavirus JC. Virol J (2006) 1.03
New sequence polymorphisms in the outer loops of the JC polyomavirus major capsid protein (VP1) possibly associated with progressive multifocal leukoencephalopathy. J Gen Virol (2005) 1.01
Cellular sialoglycoconjugates: a histochemical perspective. Histochem J (1993) 1.00
Construction of a novel JCV/SV40 hybrid virus (JCSV) reveals a role for the JCV capsid in viral tropism. Virology (2002) 1.00
Predicted amino acid sequences for 100 JCV strains. J Neurovirol (2001) 0.93
Virus-cell interaction in oligodendroglia, astroglia and phagocyte in progressive multifocal leukoencephalopathy. An electron microscopic study. Acta Neuropathol (1976) 0.88
On the discovery and chemistry of neuraminic acid and gangliosides. Chem Phys Lipids (1970) 0.81
Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09
Human non-synonymous SNPs: server and survey. Nucleic Acids Res (2002) 50.45
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature (2012) 13.71
TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study. N Engl J Med (2007) 12.24
STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med (2007) 9.80
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med (2004) 9.72
Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat Chem Biol (2008) 9.24
Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med (2008) 7.33
A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet (2001) 6.56
Medical sequencing at the extremes of human body mass. Am J Hum Genet (2007) 5.61
Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med (2008) 5.58
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS (2005) 4.07
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med (2008) 3.71
Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol (2010) 3.67
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis (2010) 3.37
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. AIDS (2014) 3.25
Dobzhansky-Muller incompatibilities in protein evolution. Proc Natl Acad Sci U S A (2002) 3.19
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
A universal trend of amino acid gain and loss in protein evolution. Nature (2005) 2.81
Widely distributed noncoding purifying selection in the human genome. Proc Natl Acad Sci U S A (2007) 2.71
Increase of functional diversity by alternative splicing. Trends Genet (2003) 2.59
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. AIDS (2007) 2.58
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Extremely low-coverage sequencing and imputation increases power for genome-wide association studies. Nat Genet (2012) 2.50
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis (2012) 2.43
Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr (2010) 2.37
Computational and statistical approaches to analyzing variants identified by exome sequencing. Genome Biol (2011) 2.32
Sequencing studies in human genetics: design and interpretation. Nat Rev Genet (2013) 2.27
Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis (2010) 2.14
Multiple actions of systemic artemin in experimental neuropathy. Nat Med (2003) 2.12
Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Chemother (2009) 2.02
A model for statistical significance of local similarities in structure. J Mol Biol (2003) 2.01
Analysis of sequence conservation at nucleotide resolution. PLoS Comput Biol (2007) 2.01
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS (2006) 1.98
Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med (2008) 1.97
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS (2009) 1.93
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr (2005) 1.87
Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78
Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. Clin Infect Dis (2011) 1.77
Real-time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol (2003) 1.75
Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res (2008) 1.73
Small fitness effect of mutations in highly conserved non-coding regions. Hum Mol Genet (2005) 1.73
HIV-1 infection and cognitive impairment in the cART era: a review. AIDS (2011) 1.72
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol (2003) 1.70
Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol Med (2008) 1.69
Quantitative analysis of the activation mechanism of the multicomponent growth-factor receptor Ret. Nat Chem Biol (2006) 1.68
Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. J Antimicrob Chemother (2011) 1.66
The mouse epididymal transcriptome: transcriptional profiling of segmental gene expression in the epididymis. Biol Reprod (2005) 1.65
Small molecule inhibition of phosphatidylinositol-3,4,5-triphosphate (PIP3) binding to pleckstrin homology domains. Proc Natl Acad Sci U S A (2010) 1.61
Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis (2011) 1.59
Affinity enhancement of an in vivo matured therapeutic antibody using structure-based computational design. Protein Sci (2006) 1.55
The interface of protein structure, protein biophysics, and molecular evolution. Protein Sci (2012) 1.54
A limited role for balancing selection. Trends Genet (2005) 1.51
Evolutionary constraints in conserved nongenic sequences of mammals. Genome Res (2005) 1.50
Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks. J Acquir Immune Defic Syndr (2005) 1.50
The power and the limitations of cross-species protein identification by mass spectrometry-driven sequence similarity searches. Mol Cell Proteomics (2003) 1.50
Metabolites: a helping hand for pathway evolution? Trends Biochem Sci (2003) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin Infect Dis (2005) 1.47
Indel-based evolutionary distance and mouse-human divergence. Genome Res (2004) 1.47
Rapid diagnosis of mycobacterial infections and quantitation of Mycobacterium tuberculosis load by two real-time calibrated PCR assays. J Clin Microbiol (2003) 1.46
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update December 2014. New Microbiol (2015) 1.45
Analysis of HIV-1- and CMV-specific memory CD4 T-cell responses during primary and chronic infection. Blood (2002) 1.45
Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. AIDS (2007) 1.44
Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. J Exp Med (2007) 1.44
The rat epididymal transcriptome: comparison of segmental gene expression in the rat and mouse epididymides. Biol Reprod (2006) 1.43
Adaptive mutations in the JC virus protein capsid are associated with progressive multifocal leukoencephalopathy (PML). PLoS Genet (2009) 1.43
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). AIDS (2006) 1.41
Positive selection at sites of multiple amino acid replacements since rat-mouse divergence. Nature (2004) 1.40
Prevalence, associated factors, and prognostic determinants of AIDS-related toxoplasmic encephalitis in the era of advanced highly active antiretroviral therapy. Clin Infect Dis (2004) 1.40
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results. Clin Infect Dis (2007) 1.39
Structure of a NEMO/IKK-associating domain reveals architecture of the interaction site. Structure (2008) 1.39
Evaluating empirical bounds on complex disease genetic architecture. Nat Genet (2013) 1.37
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Rare, low-frequency, and common variants in the protein-coding sequence of biological candidate genes from GWASs contribute to risk of rheumatoid arthritis. Am J Hum Genet (2012) 1.35
Ritonavir-boosted tipranavir demonstrates superior efficacy to ritonavir-boosted protease inhibitors in treatment-experienced HIV-infected patients: 24-week results of the RESIST-2 trial. Clin Infect Dis (2006) 1.35